Literature DB >> 9148012

Decrease in HDV endemicity in Italy.

E Sagnelli1, T Stroffolini, A Ascione, M Chiaramonte, A Craxì, G Giusti, F Piccinino.   

Abstract

BACKGROUND/AIMS: To evaluate a possible variation in hepatitis D virus endemicity in Italy, the data from a multicentre study concerning HBsAg chronic carriers first observed in 31 liver units during 1992 were compared with the corresponding figures from a similar study performed in 1987. METHODS/
RESULTS: In both studies the methodology for the recruitment of cases was the same. The overall anti-HD prevalence in 1992 was 14.4%, a significantly lower rate than that observed in 1987 (23.4%, p < 0.01). The decrease significantly (p < 0.01) affected both males and females; it occurred in all geographical areas, although to a greater extent in northern regions. It was evident in subjects below 50 years of age, but not in subjects older than 50. A significant reduction in the anti-HD prevalence was seen in all forms of chronic hepatitis.
CONCLUSIONS: These findings indicate a lower level of hepatitis D virus endemicity in Italy, probably as a consequence of the reported decreased pool of HBsAg chronic carriers, the reduced size of families, the improved socio-economic conditions and changes in intravenous drug abuser behaviour. All these factors may have affected the strength of hepatitis D virus infection which has greatly reduced the spread of the virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148012     DOI: 10.1016/s0168-8278(97)80004-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

Review 1.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

2.  Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon.

Authors:  S Ramia; M El-Zaatari; A I Sharara; F Ramlawi; B Farhat
Journal:  Epidemiol Infect       Date:  2006-12-19       Impact factor: 2.451

Review 3.  Hepatitis delta virus: Making the point from virus isolation up to 2014.

Authors:  Raffaella Romeo; Riccardo Perbellini
Journal:  World J Hepatol       Date:  2015-10-08

4.  Hepatitis delta infection in Italian patients: towards the end of the story?

Authors:  Tommaso Stroffolini; Evangelista Sagnelli; Caterina Sagnelli; Maurizio Russello; Massimo De Luca; Floriano Rosina; Bruno Cacopardo; Giuseppina Brancaccio; Caterina Furlan; Giovanni Battista Gaeta; Anna Licata; Piero Luigi Almasio
Journal:  Infection       Date:  2016-11-05       Impact factor: 3.553

5.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

6.  Impact of comorbidities on the severity of chronic hepatitis B at presentation.

Authors:  Evangelista Sagnelli; Tommaso Stroffolini; Alfonso Mele; Michele Imparato; Caterina Sagnelli; Nicola Coppola; Piero Luigi Almasio
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

Review 7.  Hepatitis D: Scenario in the Asia-Pacific region.

Authors:  Zaigham Abbas; Wasim Jafri; Sajjad Raza
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

Review 8.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  Unthought-of problems regarding hepatitis D virus infection.

Authors:  Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

10.  A study of HDV in HBsAg positive patients in Tabriz, Northwestern Iran.

Authors:  Sirus Jedary Seifi; Masoud Sabouri Ghannad
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.